Navigation Links
Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes
Date:6/29/2015

SAN DIEGO, June 29, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has been added to the Russell 2000® Small Cap, Russell 3000®, and Russell Global® Indexes. The addition to the indexes occurred at the close of trading on June 26, 2015 when the Russell Investment Group reconstituted its comprehensive set of U.S. and global indexes. Sorrento is already a member of the Russell Microcap® Index.

About the Russell Indexes.

Russell indexes are widely used by investment managers and institutional investors for index funds, and as benchmarks for active investment strategies. Approximately $5.7 trillion in assets are benchmarked to the Russell's U.S. indexes. The Russell Global Indexes reflect the performance of over 10,000 securities in 47 countries. Membership in the Russell 3000 Index, which remains in place for one year or more, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. More information on reconstitution of the Russell indexes is available on the Russell Investments website.

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical stage oncology company developing new treatments for cancer and associated pain. Sorrento recently entered into a definitive agreement with NantPharma to acquire the rights for Cynviloq™, which recently completed the TRIBECA™ study successfully, from Sorrento. The company is also developing resiniferatoxin (RTX), a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain.

In December 2014, Sorrento and NantWorks formed a global joint venture, now called Nantibody, to focus on immunotherapies for cancer. Also in December 2014, Sorrento and Conkwest, Inc., an  immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, entered into an agreement to jointly develop CAR.TNK™ (Chimeric Antigen Receptor Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases. In March 2015, Sorrento entered into a global collaboration with NantCell, a NantWorks company, to discover and develop immunotherapies against tumor neo-epitopes.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about TNK Therapeutics' prospects, including, but not limited to any statements about obtaining regulatory approval, Sorrento's expectations for adoptive cellular immunotherapies and Sorrento's collaborations with Conkwest, Nantibody and Nantcell; Sorrento's advances made in developing RTX, CAR.TNKs and human monoclonal antibodies using its proprietary G-MAB fully human antibody technology, if any; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2014, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento™, GMAB™, CAR.TNK™, TNK Therapeutics™, Ark Animal Health™, and the Sorrento logo are trademarks owned by Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

Logo - http://photos.prnewswire.com/prnh/20150105/167173LOGO

 


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento gründet Tochtergesellschaft TNK Therapeutics mit Fokus auf zelluläre Immuntherapien
2. Sorrento richt dochterbedrijf TNK Therapeutics op dat zich zal focussen op cellulaire immunotherapieën
3. Sorrento Establishes TNK Therapeutics Subsidiary with Focus on Cellular Immunotherapies
4. Sorrento Announces the Appointments of David H. Deming to the Board of Directors and Mark W. Durand as Chief Financial Officer
5. Sorrento to Present at Jefferies 2015 Immuno-Oncology Summit
6. Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer
7. Sorrento to Present at Cowen and Companys 35th Annual Health Care Conference
8. Sorrento and Conkwest Announce Exclusive Global Collaboration
9. Sorrento and Lees Pharmaceutical Enter into Exclusive China Licensing Agreement to Develop and Commercialize Anti-PD-L1 antibody
10. Sorrento Therapeutics to Present at Two Healthcare Conferences
11. Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):